Mini-Oral Abstract Presentations IV
Chairs: Chris Akolo and Minnie Kawana
14:00 – Safety and Efficacy of Tenofovir DF-Containing, Ainuovirine-Based Regimen (ANV/3TC/TDF) vs Tenofovir Alafenamide-Containing, Cobicistat-Boosted Elvitegravir-Based Regimen (E/C/F/TAF) for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 96 Results From the Phase 3, Noninferiority SPRINT Randomized Trial
Yü Wang, China
14:03 – Improvement in Drug Concentrations After an Adherence Intervention: Data From the RETAIN Study
Catherine Orrell, South Africa
14:06 – High Prevalence of Dolutegravir Resistance and Associated Factors Among People Living With HIV With Virologic Failure in North Eastern Uganda: A Retrospective Study (2022 – 2024) Saadick Ssentongo, Uganda14:09 – Early Programmatic Outcomes of 512 Self-Reported Art-Naïve People in the Era of Dolutegravir-Based Regimens
Catherine Orrell, South Africa
14:12 – Advanced HIV Disease Diagnosis and Other Predictors of Treatment Outcomes Among Newly Diagnosed People Living with HIV in Oyo State, Nigeria
Dickson Adetoye, Nigeria
14:15 – Perceptions of Changes in Risk Factors and Adherence as a Result of Engaging in a Packaged Intervention During the Early Art Initiation Period
Lora Sabin, United States
14:18 – Audience Q&A